Moderna's Dual COVID-Flu Vaccine Shows Promising Trial Results

Moderna has announced positive interim results from the Phase 1/2 trial of mRNA-1083, its combination vaccine against influenza and COVID-19. The vaccine showed strong immunogenicity against both viruses and had an acceptable safety profile. Moderna plans to begin a Phase 3 trial of mRNA-1083 in adults aged 50 and above and aims for potential regulatory approval in 2025. The company believes that combination vaccines offer an opportunity to improve compliance and convenience for individuals and healthcare systems. Influenza and COVID-19 pose significant seasonal burdens, and Moderna aims to address this threat through its combination respiratory vaccines.